---
title: "Daiwa Cuts AKESO  TP to HKD120, Reiterates Buy; Decline Exceeds Fundamentals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/305783682.md"
description: "Daiwa cut AKESO's target price to HKD120 and reiterated a Buy rating after the US FDA issued a Complete Response Letter for ivonescimab in 2L EGFRm NSCLC. The broker attributed the stock's 23% drop to weak sentiment rather than fundamentals, noting the rejected indication represents less than 10% of peak sales potential. Revenue forecasts for this specific market were removed, WACC increased, and early-stage pipeline value excluded from the DCF model."
datetime: "2026-11-17T07:58:59.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/305783682.md)
  - [en](https://longbridge.com/en/news/305783682.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/305783682.md)
generator: "portal-rs"
---

# Daiwa Cuts AKESO  TP to HKD120, Reiterates Buy; Decline Exceeds Fundamentals

Daiwa said in a research report that AKESO (09926.HK) -2.150 (-3.354%) Short selling $229.03M; Ratio 31.847% 's global partner SUMMIT Therapeutics announced on the morning of Nov 15 (US Eastern Time) that the US FDA issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for ivonescimab in combination with platinum-based chemotherapy for second-line EGFR-mutant non-small cell lung cancer (2L EGFRm NSCLC), rejecting approval for the indication. The broker said the FDA rejection was not entirely unexpected because the overall survival (OS) endpoint in the HARMONi study did not reach the pre-specified statistical significance threshold in the primary analysis, while OS has now become the most important consideration in oncology drug approvals.

Daiwa noted that AKESO (09926.HK) -2.150 (-3.354%) Short selling $229.03M; Ratio 31.847% 's share price fell 23% yesterday (16 Nov), with the decline exceeding the fundamental impact because 2L EGFRm NSCLC accounts for less than 10% of ivonescimab's US peak sales potential. The broker believed the decline was caused by multiple factors, including weak market sentiment on the day, general investors viewing the FDA rejection as below expectations, and the negative impression created by the October share placement alongside the FDA rejection. The broker believed the adjustment also provided a good entry opportunity, as multiple key data readouts are expected in 2027, including progression-free survival (PFS) and OS data for first-line squamous and non-squamous NSCLC in 1H27.

The broker reiterated its Buy rating on AKESO (09926.HK) -2.150 (-3.354%) Short selling $229.03M; Ratio 31.847% , but removed revenue forecasts for ivonescimab in global 2L EGFRm NSCLC markets after the FDA issued the CRL. It also excluded the value of early-stage pipelines from its discounted cash flow (DCF) target price calculation and raised its weighted average cost of capital (WACC) estimate from 9.4% to 9.7%. The 12-month target price was cut from HKD140 to HKD120. Key downside risks include weaker-than-expected global HARMONi-3 data for ivonescimab and earnings missing expectations. (da/u)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-11-17 12:25.)

### Related Stocks

- [09926.HK](https://longbridge.com/en/quote/09926.HK.md)
- [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md)

## Related News & Research

- [Nomura Downgrades AKESO  to Neutral, Cuts TP to HKD94](https://longbridge.com/en/news/305613245.md)
- [Akeso Says FDA Complete Response Letter May Explain Unusual Share Price Moves](https://longbridge.com/en/news/305612661.md)
- [China Accepts Akeso’s Ivonescimab Application for Biliary Tract Cancer](https://longbridge.com/en/news/305757945.md)
- [UBS: AKESO  Partner Receives FDA Complete Response Letter for ivonescimab Plus Chemotherapy BLA, Slightly Negative](https://longbridge.com/en/news/305605601.md)
- [Akeso's Gumokimab Wins China Approval for Active Ankylosing Spondylitis](https://longbridge.com/en/news/305622467.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**